[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GB2246783A - Fusion proteins containing n-terminal fragments of human serum albumin - Google Patents

Fusion proteins containing n-terminal fragments of human serum albumin

Info

Publication number
GB2246783A
GB2246783A GB9119043A GB9119043A GB2246783A GB 2246783 A GB2246783 A GB 2246783A GB 9119043 A GB9119043 A GB 9119043A GB 9119043 A GB9119043 A GB 9119043A GB 2246783 A GB2246783 A GB 2246783A
Authority
GB
United Kingdom
Prior art keywords
terminal
terminal portion
fusion proteins
serum albumin
human serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB9119043A
Other versions
GB9119043D0 (en
GB2246783B (en
Inventor
David James Ballance
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albumedix Ltd
Original Assignee
Delta Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd
Publication of GB9119043D0 publication Critical patent/GB9119043D0/en
Publication of GB2246783A publication Critical patent/GB2246783A/en
Application granted granted Critical
Publication of GB2246783B publication Critical patent/GB2246783B/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A fusion polypeptide comprising, as at least part of the N-terminal portion thereof, an N-terminal portion of HSA or a variant thereof and, as at least part of the C-terminal portion thereof, another polypeptide except that, when the said N-terminal portion of HSA is the 1-n portion where n is 369 to 419 or a variant thereof, then the said polypeptide is one of various specified entities, including the 585 to 1578 portion of human fibronectin or a variant thereof. The HSA-like portion may have additional N-terminal residues, such as secretion leader sequences (signal sequences). The C-terminal portion is preferably the 585-1578 portion of human plasma fibronectin. The N-terminal and C-terminal portions may be cleavable to yield the isolated C-terminal portion, with the N-terminal portion having served to facilitate secretion from the host.
GB9119043A 1989-04-29 1991-09-06 Fusion proteins containing n-terminal fragments of human serum albumin Expired - Lifetime GB2246783B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898909916A GB8909916D0 (en) 1989-04-29 1989-04-29 Polypeptides

Publications (3)

Publication Number Publication Date
GB9119043D0 GB9119043D0 (en) 1991-12-04
GB2246783A true GB2246783A (en) 1992-02-12
GB2246783B GB2246783B (en) 1992-10-14

Family

ID=10656000

Family Applications (2)

Application Number Title Priority Date Filing Date
GB898909916A Pending GB8909916D0 (en) 1989-04-29 1989-04-29 Polypeptides
GB9119043A Expired - Lifetime GB2246783B (en) 1989-04-29 1991-09-06 Fusion proteins containing n-terminal fragments of human serum albumin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB898909916A Pending GB8909916D0 (en) 1989-04-29 1989-04-29 Polypeptides

Country Status (12)

Country Link
EP (1) EP0470165A1 (en)
JP (1) JP2781459B2 (en)
KR (1) KR100227167B1 (en)
AU (1) AU630450B2 (en)
CA (1) CA2015687C (en)
FI (1) FI104255B (en)
GB (2) GB8909916D0 (en)
HU (1) HUT61049A (en)
IE (1) IE67651B1 (en)
IL (1) IL94243A (en)
WO (1) WO1990013653A1 (en)
ZA (1) ZA903237B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2288807A (en) * 1994-04-27 1995-11-01 British Tech Group Delta-latroinsectotoxin

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
FR2686900B1 (en) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO1994016085A2 (en) * 1992-12-30 1994-07-21 Zymogenetics, Inc. Hybrid proteins having cross-linking and tissue-binding activities
US5543308A (en) * 1994-10-18 1996-08-06 New England Biolabs, Inc. Isolated DNA encoding the FSEI restriction endonuclease and related methods for producing the same
US5877149A (en) 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
MY120425A (en) * 1996-07-26 2005-10-31 Novartis Ag Fusion polypeptides
US6423512B1 (en) 1996-07-26 2002-07-23 Novartis Ag Fusion polypeptides
US5932693A (en) * 1996-12-10 1999-08-03 Washington University Antithrombotic peptides
AU2149899A (en) 1998-01-23 1999-08-09 Novo Nordisk A/S Process for making desired polypeptides in yeast
JP4087563B2 (en) 1998-06-15 2008-05-21 ジーティーシー バイオセラピューティックス インコーポレイテッド Erythropoietin analog-human serum albumin fusion
CA2405701A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
DE60232083D1 (en) 2001-08-15 2009-06-04 Takara Bio Inc EXPANSION CULTURE PROCEDURE FOR ANTIGEN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
ES2500918T3 (en) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Albumin and interferon beta fusion proteins
CN102321579A (en) 2002-03-25 2012-01-18 宝生物工程株式会社 The method for preparing cytotoxic lymphocyte
AU2004267313B2 (en) * 2003-08-22 2009-09-24 Takara Bio Inc. Process for producing cytotoxic lymphocytes
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
WO2006067511A1 (en) 2004-12-23 2006-06-29 Novozymes Delta Limited Gene expression technique
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
EP2046367A4 (en) 2006-06-07 2009-11-11 Human Genome Sciences Inc Albumin fusion proteins
CA2657277C (en) 2006-07-13 2015-11-24 Upperton Limited Process for preparing particles of proteinaceous material
CN106986933A (en) 2009-02-11 2017-07-28 阿尔布梅迪克斯医疗公司 Albumin variants and conjugate
JP2013509170A (en) 2009-10-30 2013-03-14 ノボザイムス バイオファーマ デーコー アクティーゼルスカブ Albumin variant
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
KR102103476B1 (en) * 2011-06-24 2020-04-23 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
EP3330283A3 (en) 2012-03-16 2018-07-11 Albumedix A/S Albumin variants
EP2917233A1 (en) 2012-11-08 2015-09-16 Novozymes Biopharma DK A/S Albumin variants
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
EP3337816B1 (en) 2015-08-20 2024-02-14 Albumedix Ltd Albumin variants and conjugates
EP3538560A4 (en) * 2016-11-10 2020-06-17 Keros Therapeutics, Inc. Gdnf fusion polypeptides and methods of use thereof
BR112021008200A2 (en) * 2018-10-29 2021-12-14 Spin Therapeutics Llc Compositions and methods for alpha-1-antitrypsin disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002467A1 (en) * 1987-09-14 1989-03-23 Skandigen Ab Artificial gene coding for authentic human serum albumin, use thereof, and method of producing the same
EP0322094A1 (en) * 1987-10-30 1989-06-28 Delta Biotechnology Limited N-terminal fragments of human serum albumin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002467A1 (en) * 1987-09-14 1989-03-23 Skandigen Ab Artificial gene coding for authentic human serum albumin, use thereof, and method of producing the same
EP0322094A1 (en) * 1987-10-30 1989-06-28 Delta Biotechnology Limited N-terminal fragments of human serum albumin

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2288807A (en) * 1994-04-27 1995-11-01 British Tech Group Delta-latroinsectotoxin
GB2288807B (en) * 1994-04-27 1998-12-23 British Tech Group Production of delta-latroinsectotoxin

Also Published As

Publication number Publication date
ZA903237B (en) 1991-03-27
CA2015687C (en) 2000-08-29
HU904413D0 (en) 1992-01-28
WO1990013653A1 (en) 1990-11-15
CA2015687A1 (en) 1990-10-29
GB9119043D0 (en) 1991-12-04
FI104255B1 (en) 1999-12-15
IE67651B1 (en) 1996-04-17
FI104255B (en) 1999-12-15
KR100227167B1 (en) 1999-10-15
JPH04506598A (en) 1992-11-19
IL94243A0 (en) 1991-01-31
AU630450B2 (en) 1992-10-29
KR920701451A (en) 1992-08-11
AU5564690A (en) 1990-11-29
GB8909916D0 (en) 1989-06-14
GB2246783B (en) 1992-10-14
EP0470165A1 (en) 1992-02-12
FI915073A0 (en) 1991-10-28
IE901554L (en) 1990-10-29
JP2781459B2 (en) 1998-07-30
IL94243A (en) 1995-10-31
HUT61049A (en) 1992-11-30

Similar Documents

Publication Publication Date Title
GB2246783A (en) Fusion proteins containing n-terminal fragments of human serum albumin
HUT58370A (en) Yeast expressing systhem
CA2083271A1 (en) Fibrin binding domain polypeptides and uses and methods of producing same
CA2025598A1 (en) Chimaeric hepadnavirus core antigen proteins
YU193887A (en) PROCESS FOR OBTAINING APOLYPOPROTEINE "Al"
KR100295606B1 (en)
NO903544L (en) PROCEDURE FOR GETTING A POLYPEPTIDE ANALOGUE OF HUMAN-INTER-LEUKIN-3.
JPS646219A (en) Peptide having promoting action on activation of protein c by thrombin
BR9809416A (en) Process for cleavage of fusion proteins
DE69101486D1 (en) METHOD FOR PURIFYING RECOMBINANT POLYPEPTIDES.
WO1999002708A8 (en) Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein
AU637589B2 (en) Ancrod proteins, their production and use
IL89877A0 (en) Process for the preparation of proteins which start with n-terminal proline
EP0290029A3 (en) (19-alanine) calcitonin

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Expiry date: 20100425